Comment: Advances in lung cancer presented at ASCO 2014

Comment: Advances in breast cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Checkpoint blockade: a concept or already a reality?

Emerging pathways in immunotherapy

Myeloma genomics and Immuno-oncology

Novel targets and immune based therapy in myeloma